Reduced mu opioid receptor availability in schizophrenia revealed with [
Adult
Analgesics, Opioid
/ administration & dosage
Brain
/ diagnostic imaging
Carbon Radioisotopes
Case-Control Studies
Female
Fentanyl
/ administration & dosage
Healthy Volunteers
Humans
Male
Positron-Emission Tomography
/ methods
Radioactive Tracers
Receptors, Opioid, mu
/ metabolism
Schizophrenia
/ diagnostic imaging
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
03 10 2019
03 10 2019
Historique:
received:
20
03
2019
accepted:
04
09
2019
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
18
2
2020
Statut:
epublish
Résumé
Negative symptoms, such as amotivation and anhedonia, are a major cause of functional impairment in schizophrenia. There are currently no licensed treatments for negative symptoms, highlighting the need to understand the molecular mechanisms underlying them. Mu-opioid receptors (MOR) in the striatum play a key role in hedonic processing and reward function and are reduced post-mortem in schizophrenia. However, it is unknown if mu-opioid receptor availability is altered in-vivo or related to negative symptoms in schizophrenia. Using [
Identifiants
pubmed: 31582737
doi: 10.1038/s41467-019-12366-4
pii: 10.1038/s41467-019-12366-4
pmc: PMC6776653
doi:
Substances chimiques
Analgesics, Opioid
0
Carbon Radioisotopes
0
Carbon-11
0
OPRM1 protein, human
0
Radioactive Tracers
0
Receptors, Opioid, mu
0
carfentanil
LA9DTA2L8F
Fentanyl
UF599785JZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4493Subventions
Organisme : Medical Research Council
ID : MR/N027078/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L022176/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700995
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-A656-5QD30
Pays : United Kingdom
Références
Cereb Cortex. 2012 May;22(5):1215-23
pubmed: 21810780
Sci Rep. 2019 Feb 21;9(1):2496
pubmed: 30792460
Biol Psychiatry. 2011 Oct 15;70(8):770-6
pubmed: 21802658
Biol Psychiatry. 2017 Jul 1;82(1):8-16
pubmed: 28117049
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Synapse. 2010 Jun;64(6):478-85
pubmed: 20175222
Schizophr Res. 2017 Aug;186:29-38
pubmed: 27230288
Brain Res. 1990 Oct 22;530(2):312-6
pubmed: 2176118
Brain. 2008 May;131(Pt 5):1171-96
pubmed: 18048446
Neuroimage. 2011 Jan 1;54(1):264-77
pubmed: 20600980
Am J Psychiatry. 1988 May;145(5):578-83
pubmed: 3358462
Schizophr Res. 1990 Jul-Aug;3(4):247-51
pubmed: 2278986
Curr Treat Options Psychiatry. 2016;3:133-150
pubmed: 27376016
J Neurosci. 2015 Mar 4;35(9):3959-65
pubmed: 25740524
Mol Psychiatry. 2020 Aug;25(8):1749-1758
pubmed: 29942043
Hum Brain Mapp. 2014 May;35(5):1875-84
pubmed: 23671038
J Comput Assist Tomogr. 1985 Mar-Apr;9(2):231-6
pubmed: 2982931
Psychiatry Res. 1989 Nov;30(2):119-23
pubmed: 2616682
Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73
pubmed: 8935801
Psychopharmacology (Berl). 2009 Jul;205(1):119-28
pubmed: 19337725
Mol Pharmacol. 1994 Feb;45(2):330-4
pubmed: 8114680
Psychiatry Res. 2011 May 15;187(1-2):36-41
pubmed: 21295860
Neuropsychopharmacology. 2001 Dec;25(6):904-14
pubmed: 11750183
Fluids Barriers CNS. 2012 Aug 10;9(1):16
pubmed: 22883598
J Psychopharmacol. 2012 Sep;26(9):1185-93
pubmed: 22526685
Lancet Psychiatry. 2018 Nov;5(11):885-894
pubmed: 30322824
Eur J Nucl Med Mol Imaging. 2009 Feb;36(2):275-86
pubmed: 18779961
Neurochem Res. 1996 Nov;21(11):1333-45
pubmed: 8947923
Biol Psychiatry. 1985 Nov;20(11):1211-31
pubmed: 2996642
Neuroimage. 2018 Dec;183:1-6
pubmed: 30077742
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
Neuroimage. 2010 Dec;53(4):1197-207
pubmed: 20600983
Arch Gen Psychiatry. 1982 Jul;39(7):784-8
pubmed: 7165477
Mol Psychiatry. 2011 Aug;16(8):826-35, 785
pubmed: 21502953
Life Sci. 1988;42(18):1733-42
pubmed: 2452335
Lancet Psychiatry. 2018 Aug;5(8):664-677
pubmed: 29602739
Int J Neuropsychopharmacol. 2014 Dec;17(12):2069-74
pubmed: 24807268
Eur J Neurosci. 2007 Jun;25(11):3398-405
pubmed: 17553008
J Neurosci. 1995 Jan;15(1 Pt 2):737-49
pubmed: 7823176
J Neurosci. 2013 May 22;33(21):9140-9
pubmed: 23699524
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11603-11608
pubmed: 27671662
Brain Res Mol Brain Res. 1995 Nov;33(2):333-42
pubmed: 8750894
Mol Psychiatry. 2013 Nov;18(11):1211-7
pubmed: 23958960
Psychiatry Res. 1986 Oct;19(2):93-100
pubmed: 2431427
Transl Psychiatry. 2012 Aug 28;2:e155
pubmed: 22929597
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Am J Psychiatry. 2017 Oct 1;174(10):927-942
pubmed: 28541090
Biol Psychiatry. 2012 Sep 1;72(5):371-7
pubmed: 22386378
Am J Psychiatry. 1984 Oct;141(10):1183-9
pubmed: 6091463
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):543-58
pubmed: 25797499
Mol Psychiatry. 2014 Jul;19(7):746-7
pubmed: 24514570
Mol Psychiatry. 2015 Feb;20(2):193-200
pubmed: 25600108
Eur J Neurosci. 2006 Mar;23(6):1605-13
pubmed: 16553624
J Neural Transm. 1977;40(1):13-9
pubmed: 319204
Int J Neuropsychopharmacol. 2013 Feb;16(1):47-53
pubmed: 22397905
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9268-73
pubmed: 21576462
J Cereb Blood Flow Metab. 2014 Oct;34(10):1604-12
pubmed: 25005876
Neuropsychopharmacology. 2008 Feb;33(3):653-65
pubmed: 17487229
Psychopharmacology (Berl). 2013 Sep;229(1):105-13
pubmed: 23568577
Neuropsychopharmacology. 2003 Aug;28(8):1400-11
pubmed: 12784105
Physiol Rev. 2009 Oct;89(4):1379-412
pubmed: 19789384
J Clin Endocrinol Metab. 1990 Oct;71(4):1056-8
pubmed: 2401707
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12512-7
pubmed: 19597155
J Neurosci. 2007 Feb 14;27(7):1594-605
pubmed: 17301168
Neuropsychopharmacology. 2017 Feb;42(3):606-614
pubmed: 27510425
Brain Res. 1995 Jun 5;682(1-2):245-50
pubmed: 7552322
Neuroscience. 1993 Jun;54(3):669-80
pubmed: 8101360
Schizophr Res. 2007 Jul;93(1-3):253-60
pubmed: 17490858
Science. 2004 Jun 25;304(5679):1983-6
pubmed: 15218152
BMC Psychiatry. 2012 Aug 28;12:126
pubmed: 22925223
JAMA Psychiatry. 2015 Dec;72(12):1243-51
pubmed: 26558708
Neuron. 2015 May 6;86(3):646-64
pubmed: 25950633
Neuroscience. 2003;119(1):241-9
pubmed: 12763085
Brain Res. 1988 Nov 22;474(1):75-85
pubmed: 2905617
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
Psychoneuroendocrinology. 2018 Mar;89:59-68
pubmed: 29331800
Curr Opin Pharmacol. 2009 Feb;9(1):65-73
pubmed: 19162544
Schizophr Bull. 2016 Jul;42 Suppl 1:S90-4
pubmed: 27460622
J Neurosci. 2010 Mar 3;30(9):3391-7
pubmed: 20203198
Nucl Med Biol. 2001 Aug;28(6):733-4
pubmed: 11518656
Brain Imaging Behav. 2016 Sep;10(3):920-39
pubmed: 26487590
Curr Biol. 2012 Oct 23;22(20):1918-24
pubmed: 23000149
Neuropsychopharmacology. 2016 Jun;41(7):1742-50
pubmed: 26552847
J Psychopharmacol. 2015 Feb;29(2):97-115
pubmed: 25586400
J Mol Neurosci. 2010 May;41(1):219-22
pubmed: 20112002
J Abnorm Psychol. 2013 Aug;122(3):745-55
pubmed: 23834064
Neuropsychopharmacology. 2006 Jul;31(7):1371-81
pubmed: 16205784
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
pubmed: 3046553